MacroGenics Announces Presentation at ASCO Annual Meeting

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
MacroGenics Announces Presentation at ASCO Annual Meeting 2015

ROCKVILLE, Md., May 13, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX ), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that clinical data from its Phase 1 study of margetuximab will be presented at the 51 st Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from May 29 to June 2, 2015 in Chicago, Illinois.

MacroGenics will participate in the following poster session:

Title : Updated findings of a first-in-human, phase I study of margetuximab (M), an Fc-optimized chimeric monoclonal antibody (MAb), in patients (pts) with HER2-positive advanced solid tumors Poster Time : Saturday, May 30, 2015, from 8:00 - 11:30 AM (CT) Location : S Hall A Track: Breast Cancer Poster Board Number : 11 Abstract Number : 523 Presented by : Howard A. Burris, M.D. Additional abstract details can be found at abstracts.asco.org. A poster discussion session that will include the above poster will take place on Saturday, May 30, 2015, from 1:15 - 2:30pm (CT) at N Hall B1.

About Margetuximab

Margetuximab is an antibody that targets HER2-expressing tumors, including certain types of breast and gastroesophageal cancers. Human epidermal growth factor receptor 2, or HER2, is critical for the growth of many types of tumors. Using its Fc-Optimization platform, the Company has engineered the constant region, or Fc-region, of margetuximab to increase margetuximab's ability to kill tumor cells through an Fc-dependent mechanism, including antibody dependent cell-mediated cytotoxicity, or ADCC. In 2015, MacroGenics plans to commence a Phase 3 potential registration clinical trial with margetuximab called "SOPHIA" in patients with metastatic breast cancer expressing HER2 at the 3+ level by immunohistochemistry (IHC) or 2+ level by IHC with gene amplification and for whom therapy with other HER2-directed therapeutic agents has failed. The Company also plans to commence an exploratory Phase 1/2 study combining margetuximab with another immuno-oncology therapeutic in patients with gastroesophageal cancer.

About MacroGenics, Inc.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com . MacroGenics is a registered trademark of MacroGenics, Inc.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risk factors described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Jim Karrels, Senior Vice President, CFO MacroGenics, Inc. 1-301-251-5172, Karen Sharma, Vice President MacDougall Biomedical Communications 1-781-235-3060,

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 85

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 0

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
Atomera Preps for Key Craig-Hallum Conference

Updated Category News Views 59

Unpacking the NYC Gathering Alight, let's comb through the moving parts here. Atomera Inc., ticker NASDAQ: ATOM for those eyeing the dance of numbers, is all set to step into the limelight at the 17th Annual Craig-Hallum Alpha Select Conference on November 17, 2026. This shindig isn't just another date on the calendar; it's a strategic haunt where Atomera will rub...

Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 33

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 59

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 125

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 88

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Engrain's Geospatial Innovation Pushes Property Mapping Forward

Updated Category News Views 57

Pushing the Boundaries of Property Mapping How far can you expand the boundaries of property mapping tech? Well, Engrain seems hell-bent on finding out by cranking their innovations up a notch. The Denver-based stalwart in interactive mapping is rolling out some mind-boggling enhancements that could redefine how the multifamily housing sector operates. This isn't just...

Continue Reading
Ozelle Unveils AI-Powered Hematology Tool at MEDICA 2026

Updated Category News Views 97

Pioneering a New Era in Hematology In the fast-paced world of blood analysis, standing still means being left in the dust. Ozelle, with its AI-powered innovative tool, is making waves at MEDICA 2026 in Düsseldorf. Meet O-Cyte 1, an automated hematology analyzer that's merging high-resolution cell imaging with routine CBC (Complete Blood Count) testing. Sounds like...

Continue Reading
Univers Partners to Propel Physical AI Across Industries

Updated Category News Views 95

Univers Sets Sights on Global Physical AI Expansion Now here's a tune we've been humming for a while—AI is coming to take over the mundane, and Univers seems to think it's got the right band together to make that a full-blown concert in the built environment. Announced right in the heart of Antalya, Türkiye, at the esteemed COP31, we're seeing Univers grab hands with...

Continue Reading

Top 5 Most Recently Viewed Articles

Apirone's Transformative Year: Innovations and Achievements

Updated Category News Views 120

Apirone's Transformative Year: Innovations and Achievements As we reflect on the recent progress made by Apirone, a leading cryptocurrency services provider, it is clear that 2025 marked a groundbreaking year in the company’s evolution. With a steadfast commitment to fostering innovation and enhancing user engagement, Apirone has undertaken a series of pivotal...

Continue Reading
Green Rain Energy Enhances Capital Structure with Share Swap

Updated Category News Views 170

Green Rain Energy Takes Strategic Steps to Strengthen Capital Structure Green Rain Energy Holdings Inc. (OTCID: GREH) has made an announcement that reflects its commitment to enhancing shareholder value and addressing market dynamics. The Chief Executive Officer, Alfredo Papadakis, plans to cancel 310 million common shares held through a holding company. This bold move...

Continue Reading
Piper Sandler's Positive View on Webster Financial's Potential

Updated Category News Views 92

Positive Insights from Piper Sandler on Webster Financial Piper Sandler has reaffirmed its Overweight rating on Webster Financial Corporation (NYSE: WBS), setting a steadfast price target of $54.00. This rating reflects confidence in the bank's potential for recovery and growth, despite recent challenges faced by the company. Current Performance Analysis Despite a...

Continue Reading
City Furniture's Grand Opening Sparks Growth in Tampa Region

Updated Category News Views 158

City Furniture Celebrates Exciting Grand Opening CITY Furniture, a leading home furnishings retailer, has celebrated the successful grand opening of its expansive 120,000-square-foot showroom in Sarasota. This event not only marks a significant milestone in the company's growth but also embodies its commitment to transforming the home shopping experience in the Tampa...

Continue Reading
Celebrating Scott Alexander Rose as a Pinnacle Achiever in 2024

Updated Category News Views 238

Scott Alexander Rose Recognized as a Pinnacle Achiever 2024 Scott Alexander Rose has been prominently featured and acknowledged as a Pinnacle Achiever 2024 for his exemplary contributions to education and philanthropy. His dedication reflects a lifetime of service and commitment to making a meaningful impact. A Commitment to Education and Excellence Dr. Rose's academic...

Continue Reading